CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
The new online Learning Center with new content can still be found under the “Training” folder on ...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...